The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia

被引：10
|
作者：
Chen, Xiaojun [1 ,2 ]
机构：
[1] Fudan Univ, Dept Gynecol, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200011, Peoples R China
[2] Shanghai Key Lab Female Reprod Endocrine Related, Shanghai, Peoples R China
来源：
JOURNAL OF GYNECOLOGIC ONCOLOGY | 2019年 / 30卷 / 04期
关键词：
MANAGEMENT; WOMEN;
D O I：
10.3802/jgo.2019.30.e79
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Cost-effectiveness of a strategy starting with the levonorgestrel intrauterine system (LNG-IUS) versus a strategy starting with endometrial ablation in the treatment of heavy menstrual bleeding
    van den Brink, M. J.
    Beelen, P.
    Herman, M. C.
    Geomini, P. M.
    Dekker, J. H.
    Vermeulen, K.
    Bongers, M. Y.
    Berger, M. Y.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 105 - 106
  • [32] Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil
    Valeria Bahamondes, M.
    de Lima, Yuri
    Teich, Vanessa
    Bahamondes, Luis
    Monteiro, Ilza
    CONTRACEPTION, 2012, 86 (03) : 244 - 250
  • [33] CONSERVATIVE TREATMENT FOR ENDOMETRIAL CANCER AND COMPLEX ATYPICAL HYPERPLASIA: RISK OF INTRAUTERINE SYNECHIAE
    Mitchell, C. N. Cordeiro
    Maher, J. Y.
    Hunkler, K.
    Garbose, R. A.
    Collins, L. J.
    Christianson, M. S.
    FERTILITY AND STERILITY, 2018, 110 (04) : E55 - E56
  • [34] Factors affecting IVF outcome after conservative treatment with oral progesterone with or without LNG-IUS in patients with stage Ia endometrial adenocarcinoma
    Kim, M. J.
    Kim, J. W.
    Chang, E. M.
    Lyu, S. W.
    Lee, W. S.
    Yoon, T. K.
    Seong, S. J.
    Kim, Y. S.
    HUMAN REPRODUCTION, 2014, 29 : 341 - 341
  • [35] LNG-IUS treatment of non-atypical endometrial hyperplasia: Can Pipelle endometrial sampling be an accurate method of follow-up evaluation?
    Kim, Mi Kyoung
    Seong, Seok Ju
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) : 103 - 104
  • [36] COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN
    Lete, I
    Cristobal, I
    Febrer, L.
    Crespo, C.
    Hernandez, F. J.
    Arbat, A.
    Serrano, D.
    Brosa, M.
    VALUE IN HEALTH, 2008, 11 (06) : A423 - A423
  • [37] Efficacy of Levonorgestrel-intrauterine Releasing System Combined with Goserelin in Treatment of Atypical Endometrial Hyperplasia
    Liu, Jie
    Wang, Shanshan
    Li, Shanshan
    Liu, Xuan
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1548 - 1553
  • [38] ORAL PROGESTINS VS LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN TREATMENT OF ATYPICAL ENDOMETRIAL HYPERPLASIA
    Lee, Shi Hui
    Ling, Pearl Wee
    Goh, Charissa
    Chin, Felicia
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A186 - A186
  • [39] Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system
    Kresowik, J.
    Ryan, G. L.
    Van Voorhis, B. J.
    OBSTETRICS AND GYNECOLOGY, 2008, 111 (02): : 547 - 549
  • [40] THE COST-EFFECTIVENESS OF THE LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS, MIRENA®) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING IN THE UNITED STATES
    Ganz, M.
    Shah, D.
    Gidwani, R.
    Filonenko, A.
    Su, W.
    Pocoski, J.
    Law, A.
    VALUE IN HEALTH, 2011, 14 (03) : A107 - A107
12345